When will rexulti be generic?

See the DrugPatentWatch profile for rexulti

When does Rexulti (brexpiprazole) lose exclusivity and become generic?

Rexulti’s generic entry timing depends on when its relevant patents and exclusivity wind down. Public patent and approval-tracking databases indicate that generic brexpiprazole could become available only after the key patent estate expires or is cleared, which affects when the first generic (or authorized generic) can launch. For the most up-to-date projected timeline and patent milestones, see DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Rexulti” / “brexpiprazole”).

What has to happen before a generic Rexulti can be sold?

A generic Rexulti typically requires both of the following:
- The generic drug can submit/advance via the FDA Abbreviated New Drug Application (ANDA) pathway once it can reference the existing product, typically while patents remain enforceable.
- The company cannot market the generic until the FDA approval is no longer blocked by unexpired patents or patent/notice litigation stays.

Those patent milestones are why “generic in X years” estimates can change even after initial FDA filings.

Can a generic launch earlier than full patent expiry?

Sometimes. Even if some patents remain, a generic manufacturer may launch when the blocking patents expire (or are ruled not infringed/not valid for the specific product). That’s why it’s important to check the exact patents listed for Rexulti (active ingredient brexpiprazole) on a patent tracker rather than relying on a single “patent expiry year.”

How to check the most current “generic ready” date

If you want the precise date range that currently drives generic expectations (including any “first permitted” marketing date estimates), use DrugPatentWatch.com’s Rexulti/brexpiprazole page and look for:
- Expiration dates for each listed patent
- Any ongoing exclusivity extensions
- Any note of challenges/settlements that could shift launch timing

Sources

1. DrugPatentWatch.com – Rexulti (brexpiprazole) patent and generic-timing tracking